Executive Director, Global Medical Operations

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits. This is work that transforms the lives of patients, and the careers of those who do it. The Executive Director of Global MEG Operations will serve as the operational architect delivering BMS's Medical Evidence Generation enterprise, responsible for building a fit-for-purpose operational model designed specifically around the needs and nature of medical studies across all therapeutic areas, including oncology, hematology, immunology, cardiovascular disease, and neuroscience.   This is a builder role. The leader will lead an organization of approximately 50 and will be expected to assess the current state, redesign the organizational structure, clarify roles and accountabilities, and ensure the team is equipped to execute BMS's medical evidence generation portfolio at scale and with excellence.   The role will require a leader who has previously built and scaled operational organizations from the ground up in complex, matrixed, global pharmaceutical or biotechnology environments and can bring that proven expertise to bear immediately.  Critically, this model must be purpose-built for medical — not adapted from drug development. While development trials are designed to satisfy regulatory bodies and support product approval, medical studies serve a different purpose: generating evidence that informs clinical practice, supports medical education, and deepens understanding of disease and treatment in real-world settings. This distinction creates meaningful flexibility in how medical studies are designed and operationalized, and this leader must understand and leverage that flexibility to build a model that truly fits the work across BMS's full portfolio. The ED of MEG Operations will ensure operational excellence across the full study lifecycle — from budget conception, feasibility, and timeline planning through site activation, data collection, monitoring, and study closeout. This leader reports to the SVP and Head of Medical Evidence Generation, Managed Access Programs & Real-World Evidence and serves as a core member of the MEG, MAP & RWE Leadership Team.

1. Organizational Design & Capability Building (Priority One)   Own the enterprise-wide operational strategy for medical study execution across BMS's full portfolio — oncology, hematology, immunology, cardiovascular disease, and neuroscience — ensuring the operational model is built to serve the full diversity of evidence generation needs across the organization   Define and own the organizational architecture for MEG Operations — establishing the right structure, roles, levels, and accountability model for the team responsible for day-to-day study execution   Architect a medical-specific operational framework that is deliberately distinct from the drug development model — built around the flexibility, creativity, and evidence-focused nature of medical studies rather than the regulatory-prescribed pathways that govern development trials   Design adaptable operational frameworks tailored to each study modality — interventional, observational/non-interventional, and externally sponsored — recognizing that each requires a different operational approach, governance structure, and level of sponsor oversight   Identify talent gaps and partner with HR to address under-resourced areas and elevate capability where roles have been too junior for the complexity of the work   Ensure the model scales with BMS's evolving medical portfolio and can flex as new evidence